/PRNewswire/ -- Veravas, a leader in clinical diagnostics, today announced the general commercial availability of

/PRNewswire/ -- Veravas，临床诊断领域的领导者，今天宣布其产品已全面进入商业市场

VeraBIND, the first blood-based test designed to aid in the detection of Alzheimer's disease (AD) and other tau-related neurodegenerative disorders (tauopathies). The first-in-class assay is available now as a laboratory-developed test (LDT) through Veravas. It was validated and is performed in a CLIA / CAP certified lab..

VeraBIND，这是首个旨在帮助检测阿尔茨海默病（AD）和其他与tau蛋白相关的神经退行性疾病（tau病变）的血液检测方法。这项首创的检测现在可以通过Veravas公司以实验室开发测试（LDT）的形式获得。它已经过验证，并在CLIA/CAP认证的实验室中进行。

VeraBIND Tau is designed for use in both symptomatic and presymptomatic patients, enabling earlier diagnosis when intervention is most effective.

VeraBIND Tau 旨在用于有症状和无症状的患者，能够在干预最有效的时期实现更早的诊断。

General Commercial Release of VeraBIND Tau - Blood Test for Alzheimer's-Related Tau Pathology

VeraBIND Tau - 阿尔茨海默病相关Tau病理的血液检测商业发布

'Detecting tauopathy early gives patients and healthcare providers a better chance to take action before cognitive decline sets in,' said

“早期发现tau蛋白病变能让患者和医疗保健提供者在认知能力下降之前有更好的机会采取行动，”

John Forrest

约翰·福雷斯特

, CEO of Veravas. 'VeraBIND Tau takes a novel approach by measuring pathological tau activity—a key driver of neurodegeneration that is closely linked to near-term cognitive decline.'

Veravas首席执行官表示：“VeraBIND Tau采用了一种新颖的方法来测量病理性tau活性——这是与近期认知能力下降密切相关的神经退行性变的关键驱动因素。”

A Breakthrough in Alzheimer's Diagnostics

阿尔茨海默病诊断的突破

Until now, detecting tau pathology required invasive spinal taps or expensive tau PET imaging, which has not been practical for many patients.  VeraBIND Tau makes this information available through a convenient and accessible blood test. Other blood tests measuring amyloid plaque provide a risk indication but are not as closely correlated to near-term cognitive decline..

到目前为止，检测 tau 病理需要进行侵入性的脊椎穿刺或昂贵的 tau PET 成像，这对许多患者来说并不实际。VeraBIND Tau 通过便捷且易获取的血液检测提供了这一信息。其他测量淀粉样斑块的血液检测可以提供风险指示，但与近期认知能力下降的相关性不如 tau 检测那么高。

In an analytical verification study, the test demonstrated: 96% sensitivity, 90% specificity, 92% agreement with tau PET imaging. This makes it ideal for clinical trial screening, providers and patients looking to gain earlier insight into brain pathology and health plans hoping to better manage the brain health of their populations..

在一项分析验证研究中，该测试显示出：96% 的灵敏度、90% 的特异性、与 tau PET 成像 92% 的一致性。这使其成为临床试验筛查的理想选择，适合希望更早了解脑部病理的医疗服务提供者和患者，以及希望更好地管理其人群脑部健康的计划。

These results show that VeraBIND Tau reliably detects the abnormal tau accumulation associated with Alzheimer's and provides a VeraBIND Tau Score, a semi-quantitative measure of pathologically active tau. Validation demonstrates performance comparable to current gold-standard imaging.

这些结果表明，VeraBIND Tau 能够可靠地检测与阿尔茨海默病相关的异常 tau 蛋白积累，并提供了一个 VeraBIND Tau 分数，这是对病理活跃 tau 的半定量测量。验证结果显示其性能与当前的金标准成像相当。

Clinical Impact and Accessibility

临床影响与可及性

VeraBIND Tau is now available for use by clinicians, plans, researchers, and clinical trial sponsors. The test must be ordered under the care of a physician.

VeraBIND Tau 现已可供临床医生、计划机构、研究人员和临床试验赞助者使用。该测试必须在医生的指导下进行订购。

'This test offers a practical and innovative way to give patients and families critical information they can act on,' said

“这项测试提供了一种实用且创新的方法，为患者及其家属提供他们可以采取行动的关键信息，”

Jeff Donohue

杰夫·多诺霍

, a board-certified family physician in

，一名经委员会认证的家庭医生在

Holly Springs, Georgia

霍利斯普林斯，乔治亚州

. 'Having a clear picture of tau pathology will help guide treatment decisions, lifestyle interventions, and care planning—potentially slowing disease progression.'

“明确tau病理的情况将有助于指导治疗决策、生活方式干预和护理计划——可能减缓疾病进展。”

About VeraBIND Tau and Veravas

关于VeraBIND Tau和Veravas

VeraBIND Tau uses Veravas' proprietary

VeraBIND Tau 使用 Veravas 的专有技术

, which isolates and measures hyperphosphorylated tau aggregating to normal tau—a key pathological marker of Alzheimer's—in blood samples. This enables early detection to identify risk of cognitive decline even in cognitively normal individuals.

，该技术分离并测量血液样本中与正常tau蛋白聚集的过度磷酸化tau蛋白——这是阿尔茨海默病的一个关键病理标志物。这使得即使在认知正常的人群中，也能够通过早期检测识别出认知衰退的风险。

About Veravas

关于Veravas

Veravas is a leading innovator in clinical diagnostics focused on early detection and prognostic screening for Alzheimer's disease and other neurological conditions. The company's proprietary VeraBIND

Veravas是一家领先的临床诊断创新者，专注于阿尔茨海默病和其他神经系统疾病的早期检测和预后筛查。该公司专有的VeraBIND技术。

technology transforms challenging sample types into measurable biomarkers, enabling earlier disease detection and the development of novel diagnostic tests. Its VeraBIND Tau assay is a first-in-class blood-based test that measures the pathological activity of hyperphosphorylated tau in blood samples of cognitively normal individuals or individuals experiencing cognitive impairment which may be used to aid in the diagnosis of Alzheimer's disease.

技术将具有挑战性的样本类型转化为可测量的生物标志物，从而实现更早的疾病检测和新型诊断测试的开发。其VeraBIND Tau检测是一种首创的基于血液的测试，可测量认知正常个体或经历认知障碍个体血液样本中过度磷酸化tau的病理活性，可能用于辅助阿尔茨海默病的诊断。